Jump to content

Hákon Hákonarson (scientist)

Add links
From Wikipedia, the free encyclopedia
Hákon Hákonarson
Born1960[1]
Akureyri, Iceland[1]
Citizenship
  • Iceland
  • USA
Alma materUniversity of Iceland
Scientific career
Fields
Institutions

Hákon Hákonarson (born 1960)[1] is an Icelandic genomics researcher and physician. He is the founder and director of the Center for Applied Genomics, endowed chair in genomics at the Children's Hospital of Philadelphia, and a professor of pediatrics at the Perelman School of Medicine at the University of Pennsylvania.

Biography

[edit]

Hákon was born in Akureyri.[1] He studied at the Akureyri Junior College and received a medical degree from the University of Iceland in 1986.[1] He completed a pediatrics residency at the University of Connecticut and then a pediatric pulmonology fellowship at the University of Pennsylvania.[1][2] He received a PhD from the University of Iceland in 2002.[1]

DeCode

[edit]

In 1998 he returned to Iceland to join the Icelandic genetics research firm DeCode.[3] Alongside that he worked as a pediatrics attending at the National University Hospital of Iceland.[3] Hákon became vice president of clinical sciences and development at DeCode.[4]

Center for Applied Genomics

[edit]

Hákon founded the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia in 2006. The hospital has committed to genomically characterizing over 100,000 children with CAG, which has resulted in the development of new rare disease therapies.

In 2009, TIME listed his autism gene discovery project, reported in Nature in 2009, among the "top 10 medical breakthroughs" of that year.[5] Hakonarson's paper on a novel precision based therapy in rare lymphatic disorders was awarded among the Top 10 clinical/translational papers in 2019 by the Clinical Research Forum.[6][7]

Hakonarson's NFC-1 program addressing mGluR signaling in a subset of patients with ADHD and autism, was acquired by Medgenics in 2015,[8] following a proof-of-concept study based on genetic stratification.

He is a highly cited researcher with an h-index of 179 as of 2024.[9]

He is also an attending physician in pulmonary medicine at the Children's Hospital of Philadelphia.

References

[edit]
  1. ^ a b c d e f g "Dr. Hákon Hákonarson lungnasérfræðingur barna hlýtur viðurkenningu úr sjóði Óskars Þórðarsonar barnalæknis | Sjóðir og styrkir Háskóla Íslands". sjodir.hi.is. Retrieved 2021-11-07.
  2. ^ "Hakon Hakonarson | Institute for Translational Medicine and Therapeutics | Perelman School of Medicine at the University of Pennsylvania".
  3. ^ a b Akureyri, Háskólinn á. "Starfsemi Arctic Therapeutics komin á fullt". Háskólinn á Akureyri (in Icelandic). Retrieved 2021-11-07.
  4. ^ "Hakon Hakonarson - Center for Applied Genomics". caglab.org. Archived from the original on August 11, 2020. Retrieved 2021-11-07.
  5. ^ Park, Alice (8 December 2009). "Time Magazine, Top 10 of Everything: Medical Breakthroughs". Time.
  6. ^ "Clinical Research Forum: Top 10 Clinical Research Achievement Awards - Top 10 Awardees".
  7. ^ "CHOP Researchers Reverse Severe Lymphatic Disorder in Patient with Noonan Syndrome by Targeting Genetic Pathway".
  8. ^ "MDGN: neuroFix Acquisition Could Be A Needle-Mover, September 11, 2015".
  9. ^ "Hakon Hakonarson - Google Scholar Citations". scholar.google.com.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hákon_Hákonarson_(scientist)&oldid=1257910868"